NEW YORK (GenomeWeb News) – Diaxonhit and XDx today announced that they have signed a memorandum of understanding that would provide an exclusive license to Diaxonhit for XDx's AlloMap Molecular Expression Testing technology in Europe.
As a result, Diaxonhit would become XDx's exclusive partner on the continent.
AlloMap is a gene expression, blood-based test for identifying heart transplant recipients with a low probability of acute cellular rejection. The test was cleared by the US Food and Drug Administration in 2008 and CE marked in Europe in 2011.
As part of the deal, XDx would receive an upfront payment from Diaxonhit upon the signing of a definitive agreement, as well as future royalties and milestone payments based on European sales. Other terms of the agreement were not disclosed.
AlloMap will be performed in Europe by an unnamed "internationally recognized French laboratory," the partners said.
"The agreement reached with Diaxonhit will have great benefit for heart transplant recipients throughout Europe," Peter Maag, CEO of Brisbane, Calif.-based XDx, said in a statement. "With our European CARGO II validation study completed in 2012, Diaxonhit can build on the tremendous efforts XDx has invested in AlloMap."
Diaxonhit, based in Paris, is a biotech firm formed in late 2012 when Exonhit acquired InGen BioSciences for $23.1 million.